Developer · 002262.SZ · China

Jiangsu Nhwa Pharmaceutical Co., Ltd.

CNS-focused pharmaceutical company based in Xuzhou, Jiangsu, China, listed on the Shenzhen Stock Exchange (002262, 恩华药业). Develops and markets anaesthesia, analgesia and psychiatric/neurological drugs, and reports 20+ innovative drug projects in development, including NH102 (depression, Phase 2 completed), NHL35700 (schizophrenia, Phase 3), NH130 (Parkinson's disease psychosis) and the YH1910 programs in depression.

nhwa-group.com ↗

1compound
1program
1indication
Phase 2lead asset

Phase distribution

  • Phase 21

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Catalysts · 0 upcoming · 1 reported

Recently reported

  • 2026-10-11met

    NH102forMajor depressive disorderFull results

    Phase 2 proof-of-concept in MDD: NH102 30 mg beat placebo on HAMD-17 at week 6 (difference -2.8, P=0.036); lower doses not significant; not different from duloxetine.

    source ↗

Recent activity

  • Oct 11, 2026ReadoutNH102·Major depressive disordermetPhase 2 proof-of-concept in MDD: NH102 30 mg beat placebo on HAMD-17 at week 6 (difference -2.8, P=0.036); lower doses not significant; not different from duloxetine.source ↗
  • Sep 12, 2025Phase changeNH102·Major depressive disorderPhase 2NCT06842992 completed (primary completion 2025-07-30, study completion 2025-09-12). Nhwa's 2026 interim report lists NH102 tablet among projects that have completed Phase II.source ↗
  • Dec 4, 2024Phase changeNH102·Major depressive disorderPhase 2Phase 2 dose-finding trial NCT06842992 (NH102-21) in major depressive disorder started; 243 enrolled.source ↗

Competitive landscape

Other companies developing against Jiangsu Nhwa Pharmaceutical Co., Ltd.'s targets or indications.